Doctor explains true reality of 'Ozempic penis' as study shows average penis size increasing
The term 'Ozempic penis' has been tossed around in recent months
A doctor has explained the true reality of 'Ozempic penis' after a study revealed that the average penis size has increased.
It was previously reported that the average size of a British penis increased by 0.46 inches, from 5.17 inches to 5.63, between 2022 and 2024.
It comes amid talk surrounding 'Ozempic penis', with many online bizarrely claiming that taking the drug can 'increase' the size of one's manhood.
Ozempic, an injection marketed for people with type 2 diabetes to help them manage their blood sugar levels, has become popular in recent years among those hoping to lose weight.
Advert
However, it has never been approved for weight loss - unlike other drugs, such as Mounjaro and Wegovy.
While some users have suggested penis size can increase because of the use of Ozempic, the reality is that it’s down to weight loss giving the illusion of a bigger penis.
Dr Jen Caudle, 'America's family doctor', explained on her YouTube channel: "I am not aware of any data that these medications cause an increase in penis size. That’s not something they do. However, I think as men are losing weight, their penis is appearing larger.
"One way to help your penis look larger is losing weight. Why and how? It’s because the fat pad around your scrotal area, as that shrinks, your penis often looks larger. As men are losing weight, the penis is looking larger."
Other doctors have agreed with this opinion, including Dr Richard Viney, who told Diabetes.co.uk: "Men’s penises shorten as they get older (due to) increasing body fat and increasing prostate size drawing the penis back into the body.
"It is theoretically possible new drugs like Ozempic and Wegovy, which are used to treat diabetes and obesity respectively and can cause people to lose weight, could also be a factor. As men lose weight, their penises appear larger."
In a statement provided to UNILAD, Novo Nordisk, the manufacturer of Ozempic, said: "Patient safety is of the utmost importance to Novo Nordisk, and we recommend patients take these medications for their approved indications and under the supervision of a healthcare professional. We continuously collect safety data on our marketed GLP-1 receptor agonists medicines and work closely with the authorities to ensure patient safety. As part of this work, we continue to monitor reports of adverse drug reactions through routine pharmacovigilance.
"We recommend that any patient experiencing side effects while taking GLP-1 RA medicines, including Wegovy®▼and Ozempic® (semaglutide injection), report them to their healthcare provider and via the MHRA Yellow Card scheme: https://yellowcard.mhra.gov.uk/."
Callum Jones